Pyrvinium is a chemically defined substance encountered in pharmaceutical manufacturing whose health-based exposure limit derivation requires integration of pharmacological, toxicokinetic, and general toxicological data to identify the most relevant point of departure. The quality and completeness of the toxicological database for Pyrvinium directly influences the magnitude of uncertainty factors applied and the confidence in the resulting PDE value. Periodic review of new published data and post-market clinical safety signals ensures that the OEL for Pyrvinium remains protective as scientific knowledge develops.
The intraspecies uncertainty factor F2 for Pyrvinium covers the range of pharmacokinetic and pharmacodynamic variability within the human population, ensuring the derived PDE is protective for sensitive subgroups including paediatric patients with immature CYP450 activity, elderly patients with reduced hepatic and renal clearance, patients with organ impairment affecting Pyrv
